Business
Mesoblast shares tumble again as investors pre-empt FDA – afr.com
The biotech’s management team will argue the case for approval of its cellular therapy at a make-or-break meeting with the FDA on Thursday.
Remestemcel-L also showed early signs of helping seriously ill coronavirus patients.
If approved, it would be the first allogenic stem cell product launched in a mega US market, where regulators are traditionally more sceptical over stem cell science. Mesoblast’s product is already approved in Japan.
The stock price tanked after the FDA released two briefing documents on Tuesday, which cast doubt over the clinical evidence.
OneVentures managing partner Paul Kelly said the FDA had pinged Mesob…
-
Business14 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business10 hours ago1 ASX dividend stock down 43% I’d buy right now
-
General20 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts
-
Noosa News10 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred